Praxis secures two FDA PDUFA dates: relutrigine Sept 2026, ulixacaltamide Jan 2027

The FDA has set a PDUFA target action date of January 29, 2027 for ulixacaltamide, a treatment for Essential Tremor that has received Breakthrough Therapy Designation. This represents a near-term regulatory milestone for the company's lead asset targeting a market with no ET-specific FDA-approved therapies and an estimated 7 million U.S. patients.

The FDA has set a PDUFA target action date of September 27, 2026 for relutrigine under Priority Review, for treatment of SCN2A- and SCN8A-DEE (developmental & epileptic encephalopathy). The NDA was accepted following early stoppage of the EMBOLD study at interim analysis due to positive results. This is the company's nearest-term potential approval.

The company projects peak sales potential exceeding $20 billion across its four late-stage assets: ulixacaltamide (>$10B), relutrigine (>$5B), vormatrigine (~$1B), and elsunersen (>$4B). The presentation indicates projected commercial launches spanning 2026-2028, with two products having pending PDUFA dates in 2026-2027.

The company disclosed that its cash runway extends into 2028, providing financial visibility through the anticipated commercial launches of its four late-stage assets. This runway covers the two pending PDUFA dates in September 2026 and January 2027, as well as ongoing pivotal trials for vormatrigine and elsunersen.

The company expects topline data from the EMERALD study in Q4 2026, evaluating relutrigine in phenotypic DEEs regardless of etiology. This 160-patient randomized trial targets a broader DEE market of over 200,000 U.S. patients, potentially expanding relutrigine's addressable market beyond the SCN2A/8A indications covered by the September 2026 PDUFA.

The FDA accepted Praxis's new drug application for ulixacaltamide to treat Essential Tremor, setting a PDUFA target action date of January 29, 2027. Ulixacaltamide received Breakthrough Therapy Designation in December 2025 and was the first investigational therapy to show positive Phase 3 results in Essential Tremor, a movement disorder affecting approximately $1.4 billion seven million U.S. patients. The company is accelerating commercial preparations including hiring leadership, building distribution networks, and establishing commercial inventory ahead of the potential launch.

The FDA accepted Praxis's NDA for relutrigine with priority review, setting a PDUFA target action date of September 27, 2026, for treatment of SCN2A and SCN8A developmental and epileptic encephalopathies. If approved, relutrigine would be the first therapy for these conditions and eligible for a Pediatric Review Voucher. The drug has received Breakthrough Therapy Designation and Orphan Drug Designation. Commercial preparations are progressing including hiring, inventory build, patient support programs, and payer engagement.

Topline results from the EMBRAVE Part A Phase 1/2 study showed elsunersen achieved a statistically significant 77% placebo-adjusted reduction in monthly seizures in early-seizure-onset SCN2A-DEE patients. The majority of treated patients achieved meaningful seizure reduction or freedom, and all patients showed improvements in developmental measures including sleep, motor function, muscle tone, attention or neuropsychomotor development, with no such improvements observed in the placebo group. The drug was well-tolerated with no drug-related serious adverse events, discontinuations, or neuroinflammation signals.

Praxis reported cash, cash equivalents and marketable securities of $1.4 billion as of March 31, 2026, up $473.9 million from year-end 2025, primarily from a January 2026 follow-on public offering and interest income. The company expects this cash position to fund operations into 2028. Net loss for Q1 2026 was $92.6 million compared to $69.3 million in Q1 2025, with the increase driven by higher R&D expenses ($78.0 million vs $60.8 million) and G&A expenses ($27.9 million vs $13.9 million).

Praxis outlined multiple near-term clinical milestones: POWER1 topline results for vormatrigine in focal onset seizures expected in Q2 2026, EMERALD study results in broad DEEs expected in Q4 2026 (recruitment complete), POWER2 topline results anticipated in 2027, POWER3 monotherapy study to commence in H1 2026, and EMBRAVE3 registrational trial topline results expected in 2027. The company also expects to nominate development candidates for three early-stage ASO programs (PRAX-080, PRAX-090, PRAX-100) in H1 2026.